Demant A/S (OTCMKTS:WILYY) Sees Strong Trading Volume – Time to Buy?

Demant A/S Unsponsored ADR (OTCMKTS:WILYY) shares saw unusually-high trading volume on Tuesday . Approximately 653 shares traded hands during trading, an increase of 26% from the previous session’s volume of 517 shares.The stock last traded at $21.9875 and had previously closed at $22.50.

Analyst Upgrades and Downgrades

WILYY has been the topic of a number of recent research reports. Zacks Research raised Demant A/S to a “hold” rating in a research report on Friday, June 26th. Morgan Stanley raised Demant A/S from an “equal weight” rating to an “overweight” rating in a report on Tuesday, June 23rd. UBS Group downgraded Demant A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 22nd. Finally, Sanford C. Bernstein lowered Demant A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Demant A/S has a consensus rating of “Moderate Buy”.

Demant A/S Stock Performance

The company has a quick ratio of 1.00, a current ratio of 1.36 and a debt-to-equity ratio of 1.65. The company’s fifty day simple moving average is $20.89 and its 200-day simple moving average is $17.72.

Demant A/S Company Profile

Demant A/S is a Denmark-based global hearing health care company specializing in the development, manufacture and distribution of hearing solutions and audiological diagnostic instruments. The company’s flagship brands include Oticon, Bernafon and Sonic, which offer a range of hearing aids designed to address various levels of hearing loss. In addition to personal hearing devices, Demant provides diagnostic equipment such as audiometers and tympanometers, supporting hearing care professionals in accurate assessment and fitting of hearing solutions.

Beyond hearing aids and diagnostics, Demant’s product portfolio extends to hearing implants—cochlear and bone-anchored systems—through its Oticon Medical division.